Michaelson Jennifer 4

What Happened

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics (CGEM), sold 1,780 shares on February 25, 2026. The weighted average price was $14.14 per share for total proceeds of approximately $25,169. The Form 4 reports the transaction as an open‑market or private sale (code S).

Key Details

• Transaction date: 2026-02-25; Form filed: 2026-02-26 (timely filing).
• Price: weighted average $14.14; individual trade prices ranged from $13.89 to $14.35 (see footnote F2).
• Proceeds: ~$25,169 for 1,780 shares.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — sale was effected under a pre‑established Rule 10b5‑1 trading plan (established Aug 7, 2025). F2 — price is a weighted average; Reporting Person can provide a per‑trade breakdown on request.
• Transaction code: S = Sale.

Context

• The sale was executed under a 10b5‑1 plan, which typically means the trades were pre‑planned and scheduled in advance rather than reflecting contemporaneous insider views. Sales are common for liquidity or diversification reasons; purchases generally convey stronger positive signals for investors. This filing shows a routine sale and does not by itself indicate management sentiment about Cullinan’s prospects.